Brad Rosbrook
Overview
Explore the profile of Brad Rosbrook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Veiga F, Szmulewitz R, Holzbeierlein J, Azad A, Iguchi T, Villers A, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):860-869.
PMID: 38072761
Background: In ARCHES, treatment intensification of androgen deprivation therapy (ADT) with enzalutamide versus placebo improved clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the benefits and tolerability of enzalutamide...
2.
Rini B, Atkins M, Choueiri T, Teresi R, Rosbrook B, Thakur M, et al.
Future Oncol
. 2023 Aug;
19(40):2623-2629.
PMID: 37526095
Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell...
3.
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, et al.
Eur Urol
. 2023 May;
84(2):229-241.
PMID: 37179240
Background: Few phase 3 studies have evaluated optimal systemic treatment strategies for patients with oligometastatic hormone-sensitive prostate cancer (HSPC), who may be at risk of undertreatment. Objective: To evaluate outcomes...
4.
Armstrong A, Rosbrook B, Yamada S
J Clin Oncol
. 2022 Aug;
40(36):4279-4280.
PMID: 35985006
No abstract available.
5.
Stenzl A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al.
Prostate
. 2022 Jun;
82(13):1237-1247.
PMID: 35675470
Background: Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival versus ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in ARCHES (NCT02677896). While health-related quality of life...
6.
Armstrong A, Azad A, Iguchi T, Szmulewitz R, Petrylak D, Holzbeierlein J, et al.
J Clin Oncol
. 2022 Apr;
40(15):1616-1622.
PMID: 35420921
JCO In primary analysis, enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC); however, overall survival data were immature. In...
7.
Azad A, Armstrong A, Alcaraz A, Szmulewitz R, Petrylak D, Holzbeierlein J, et al.
Prostate Cancer Prostatic Dis
. 2021 Aug;
25(2):274-282.
PMID: 34420037
Background: While enzalutamide plus androgen deprivation therapy (ADT) significantly reduces the risk of radiographic progression-free survival (rPFS) and improves overall survival in metastatic hormone-sensitive prostate cancer (mHSPC), the efficacy in...
8.
Freedland S, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, et al.
BMJ Open
. 2021 Aug;
11(8):e046588.
PMID: 34385241
Introduction: Limited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate cancer. In the absence of overt metastases, patients with non-metastatic...
9.
Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, et al.
Int J Urol
. 2021 May;
28(7):765-773.
PMID: 33955599
Objective: To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer. Methods: A post-hoc analysis of the Japanese subgroup in...
10.
Rini B, Atkins M, Choueiri T, Thomaidou D, Rosbrook B, Thakur M, et al.
Clin Genitourin Cancer
. 2021 May;
19(5):e306-e312.
PMID: 33947608
Introduction: Combined axitinib and immuno-oncology (IO) therapy is approved for first-line advanced renal cell carcinoma. Overlapping toxicities represent a clinical challenge. Calculating the time to resolution (TTR) of common axitinib-related...